Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the Striatum

Figure 1

Effects of levetiracetam on abnormal involuntary movements (AIMs) induced by L-DOPA in hemiparkinsonian rats. Animals were assessed on days 1, 3, 5, 7, 9, 11, and 14 following L-DOPA methyl ester (12 mg/kg) plus benserazide-HCl (3 mg/kg) (i.p.). Two hours prior to each L-DOPA injection, animals received levetiracetam 0 (control group, vehicle injection), 15, 30, or 60 mg/kg by gavage. Total AIMs scores (a) include orofacial (b), axial (c), and limb (d) AIMs scores. Rotational behavior (contralateral turns, (e)) shows that levetiracetam induced no changes in the antiparkinsonian action of L-Dopa. Values are mean ± SEM. and versus control group ( per group; LEV: levetiracetam).

(a)

(b)

(c)

(d)

(e)